Cytogenetic Technologists

29-2011.01
Rank #526 of 923 scored · top 57% by substitution

Analyze chromosomes or chromosome segments found in biological specimens, such as amniotic fluids, bone marrow, solid tumors, and blood to aid in the study, diagnosis, classification, or treatment of inherited or acquired genetic diseases. Conduct analyses through classical cytogenetic, fluorescent in situ hybridization (FISH) or array comparative genome hybridization (aCGH) techniques.

Sub-scores

0–100 · band = confidence interval from rater disagreement

Substitution26
Exposure27
Augmentation51

Substitution — the headline: capability discounted by cost, barriers and adoption.

Exposure — technical capability alone, regardless of whether anyone deploys it.

Augmentation — how much AI assists without replacing. High here + moderate substitution = a changing job, not a disappearing one.

Tasks on the substitution scale

30 rated tasks, binned by substitution score.

Position among all scored occupations

Distribution of 923 occupation scores; the marker is this occupation.

Tasks with substitution ≥ 70

7%

Run 1.0.0-draft.1 · computed 2026-08-05 · rater panel: claude-sonnet-5, claude-haiku-4-5-20251001 · intervals span rater disagreement.

Why this score

The five weighted dimensions of the composite, averaged across this occupation's tasks (importance-weighted, panel mean). Exact weights and formulas: /api/v1/methodology.

Task automatabilityw 35%28

panel mean rating 2.1/5 → substitution pressure 28/100

Technical feasibility todayw 20%24

panel mean rating 1.9/5 → substitution pressure 24/100

Cost vs. human wagew 15%26

panel mean rating 2.0/5 → substitution pressure 26/100

Adoption barriersw 20%inverted — strong barriers lower the score25

panel mean rating 4.0/5 (barrier strength) → substitution pressure 25/100

Sector adoption velocityw 10%25

panel mean rating 2.0/5 → substitution pressure 25/100

Task breakdown (30 tasks)

Substitution pressure per task, weighted by O*NET importance in the composite. Expand a task for the full rater audit trail — every rating, every model, every rationale.

Input details of specimens into logs or computer systems.

72

CI 67–76 · exposure 75 · augmentation 75 · importance 4.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Laboratory automation has increased steadily, but adoption of AI-assisted data entry remains uneven. Some large reference labs and hospital systems have deployed LIMS integrations; smaller labs lag. Overall adoption is in the pilot-to-early-production phase rather than deep market penetration.
Sector adoption velocityclaude-sonnet-53/5Clinical and diagnostic laboratories are moderately digitized with LIMS adoption common, but many cytogenetic labs still rely on manual entry or semi-automated workflows, placing adoption in the middle range.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can assist technologists by pre-populating fields, flagging anomalies, and accelerating data capture from scanned or photographed specimen labels, freeing technologists to focus on accuracy verification and exception handling. This augmentation raises overall throughput without removing human oversight.
Augmentation potentialclaude-sonnet-54/5AI-assisted data entry, autofill, and validation tools significantly speed up specimen logging and reduce transcription errors while technologists retain oversight of accuracy.
Task automatabilityclaude-haiku-4-5-202510014/5Inputting specimen details into logs or computer systems is predominantly data entry work with well-defined, structured formats. Current AI systems can reliably extract specimen information from source documents and populate database fields, achieving substantial time savings with minimal manual oversight.
Task automatabilityclaude-sonnet-54/5Data entry of specimen details into logs or LIMS systems is a structured, repetitive text/data task that AI-enabled automation (OCR, barcode integration, LIMS APIs) can handle with substantial time savings.4/5 reflects that full end-to-end automation may still need occasional human verification for edge cases.
Adoption barriersclaude-haiku-4-5-202510013/5Clinical and diagnostic labs have regulatory requirements (CLIA, CAP) around data integrity and traceability, which introduce requirements for audit trails and validation. However, these barriers are manageable through system design; they do not require human sign-off on every entry, only governance controls.
Adoption barriersclaude-sonnet-52/5No licensure is required specifically for data entry, though lab data integrity and CLIA compliance require accuracy safeguards, creating mild procedural friction rather than hard legal barriers.
Cost vs. human wageclaude-haiku-4-5-202510015/5AI-driven data entry and document processing cost a fraction of technician time per specimen logged. With automation amortized across high-volume specimen processing, the cost per specimen is orders of magnitude lower than manual technician labor.
Cost vs. human wageclaude-sonnet-54/5Automated specimen logging via barcode/LIMS integration is far cheaper per transaction than manual technologist data entry time, though initial system integration and maintenance costs temper a perfect score.
Technical feasibility todayclaude-haiku-4-5-202510014/5Deployed products like optical character recognition (OCR) systems and laboratory information management system (LIMS) integrations with AI preprocessing are production-ready in clinical labs. Error rates are low for structured data entry, though some edge cases and handwritten notes may require human review.
Technical feasibility todayclaude-sonnet-54/5Laboratory information management systems (LIMS) with barcode scanning, OCR, and automated data capture are widely deployed in clinical labs today, reliably handling specimen logging in production settings.

Create chromosome images using computer imaging systems.

71

CI 64–79 · exposure 83 · augmentation 88 · importance 4.6/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Clinical and research laboratories have rapidly adopted automated microscopy and imaging systems over the past decade; many high-volume cytogenetics facilities use automated slide scanning and AI-assisted image analysis as standard workflow components.
Sector adoption velocityclaude-sonnet-53/5Clinical laboratory settings adopt automation steadily but cautiously due to regulatory and validation requirements, resulting in moderate, not rapid, adoption of automated imaging tools.
Augmentation potentialclaude-haiku-4-5-202510014/5AI imaging systems significantly augment technologist productivity by automating focus, exposure, and basic image processing, allowing technologists to focus on quality review, abnormality flagging, and interpretation rather than manual image acquisition.
Augmentation potentialclaude-sonnet-55/5Automated imaging software dramatically speeds up chromosome image capture, enhancement, and arrangement, letting technologists focus on interpretation and quality control rather than manual image creation.
Task automatabilityclaude-haiku-4-5-202510015/5Chromosome imaging via computer systems is a highly structured, image-capture and processing workflow that current AI systems (including image analysis and microscopy automation) can perform end-to-end with significant time savings. Standard preprocessing, focus detection, and image enhancement are fully automatable with demonstrated tools.
Task automatabilityclaude-sonnet-54/5Capturing microscope images, karyotyping, and arranging chromosome images is largely a technical imaging workflow that existing automated cytogenetic imaging software already performs with substantial time savings over manual work.
Adoption barriersclaude-haiku-4-5-202510013/5Regulatory oversight (FDA/CAP requirements for clinical cytogenetics) and established quality control protocols require human review and sign-off of results, creating moderate adoption friction. However, automation of the image capture itself is not legally barred.
Adoption barriersclaude-sonnet-53/5Clinical lab results require certified technologist review and lab accreditation standards (CAP/CLIA), creating moderate oversight requirements even though the imaging step itself is technically automatable.
Cost vs. human wageclaude-haiku-4-5-202510014/5Automated imaging systems have high capital cost but low per-image inference cost once deployed; ongoing cost per chromosome image set is substantially cheaper than technician labor when amortized across volume, though the initial capital investment is significant.
Cost vs. human wageclaude-sonnet-53/5Specialized imaging systems have significant upfront capital and licensing costs, software maintenance, and require technologist oversight, so while cheaper than fully manual imaging, they are not order-of-magnitude cheaper once amortized.
Technical feasibility todayclaude-haiku-4-5-202510014/5Deployed products for automated microscopy imaging, slide scanning, and image preprocessing exist and perform reliably in laboratory settings, though some manual review and quality control steps remain standard practice. Production-grade systems are in use but typically require oversight workflows.
Technical feasibility todayclaude-sonnet-54/5Commercial cytogenetic imaging platforms (e.g., automated metaphase finders and karyotyping software) are deployed in clinical labs today and reliably automate capture, image enhancement, and chromosome arrangement, though human review remains standard.

Input details of specimen processing, analysis, and technical issues into logs or laboratory information systems (LIS).

67

CI 60–74 · exposure 70 · augmentation 75 · importance 4.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Clinical laboratories and medical facilities have rapidly adopted LIS with automated specimen logging; major vendors (e.g., Illumina, Thermo Fisher) ship integrated systems, and digitization of lab workflows is standard in healthcare.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory settings adopt digitization steadily but cautiously due to regulatory validation requirements and legacy LIS systems, making adoption slower than in typical white-collar sectors.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can assist technologists by auto-populating fields from specimen images, flagging abnormal technical parameters, and suggesting issue categories, significantly reducing manual entry time while the technologist validates and adds expert context.
Augmentation potentialclaude-sonnet-54/5AI-assisted transcription, templated logging, and auto-population from instrument outputs can meaningfully speed up documentation while the technologist verifies and finalizes entries.
Task automatabilityclaude-haiku-4-5-202510014/5Data entry and logging of structured specimen processing details is highly automatable; computer vision can read labels, workflow systems can timestamp events, and structured fields map directly to database schemas. However, complex technical issues may require human judgment to categorize correctly, preventing a full 5.
Task automatabilityclaude-sonnet-54/5Structured data entry into LIS from processing/analysis records is largely templated documentation work that current AI (especially with LIS integration/OCR/voice-to-text) can handle with high time savings, though some technical judgment on anomalies remains.
Adoption barriersclaude-haiku-4-5-202510013/5Lab accreditation standards (CAP, CLIA) require documented, auditable specimen tracking, creating oversight and validation requirements; liability concerns around specimen identification errors add friction but do not absolutely require licensed personnel for data entry itself.
Adoption barriersclaude-sonnet-53/5Lab data entry isn't strictly required to be performed by a licensed technologist, but CAP/CLIA documentation standards and accuracy requirements for clinical records create moderate oversight friction.
Cost vs. human wageclaude-haiku-4-5-202510015/5Automated specimen tracking, barcode readers, and AI-assisted data entry are orders of magnitude cheaper than human data-entry labor, especially at scale across thousands of specimens annually.
Cost vs. human wageclaude-sonnet-54/5Automated data entry/transcription tools cost far less per record than technologist time spent on manual logging, though initial LIS integration and validation add some overhead.
Technical feasibility todayclaude-haiku-4-5-202510014/5Laboratory information systems with barcode scanning and automated logging are deployed in production across clinical labs; however, error detection and resolution of ambiguous entries still requires human oversight, so reliability is not yet at maximum maturity.
Technical feasibility todayclaude-sonnet-53/5LIS and lab middleware products offer structured data entry and auto-population features, but full automation of narrative technical-issue logging in cytogenetics labs is not yet standard or fully reliable in production.

Archive case documentation and study materials as required by regulations and laws.

61

CI 48–74 · exposure 62 · augmentation 63 · importance 3.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Healthcare and laboratory sectors have invested heavily in automated document and specimen management systems over the past decade, with widespread adoption of digital archival in pathology labs and compliance infrastructure being standard practice.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory settings, especially specialized cytogenetics labs, have historically slower digital transformation and cautious adoption of new automated systems due to regulatory and validation burdens.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist technologists by auto-classifying documents, suggesting appropriate archive locations, and flagging compliance gaps, improving accuracy and reducing manual review time without removing human oversight of critical regulatory decisions.
Augmentation potentialclaude-sonnet-54/5AI-driven document management, automated indexing, and retrieval tools can significantly streamline archiving workflows and reduce manual filing burden while technologists retain oversight for compliance.
Task automatabilityclaude-haiku-4-5-202510014/5Archiving case documentation and study materials involves routine file organization, metadata tagging, and storage compliance—tasks that RPA and document management systems can automate nearly end-to-end with minimal human intervention, achieving substantial time savings.
Task automatabilityclaude-sonnet-53/5Archiving documentation involves structured data entry, indexing, and file management that AI/automation systems can largely handle, though ensuring regulatory-compliant retention and metadata still requires setup and oversight.'
Adoption barriersclaude-haiku-4-5-202510013/5Regulatory requirements (HIPAA, CAP, CLIA compliance) and liability concerns around lost or misfiled specimens create moderate friction; however, these are addressed by standardized compliant systems rather than legal prohibition of automation itself.
Adoption barriersclaude-sonnet-53/5Regulatory requirements (e.g., CLIA, CAP) mandate specific retention practices and audit trails, requiring accountable oversight, though the archiving task itself is not restricted to licensed personnel by law.
Cost vs. human wageclaude-haiku-4-5-202510015/5Automated document archival costs a small fraction of human technologist labor—scanning, OCR, metadata tagging, and compliance verification via AI agents are orders of magnitude cheaper than manual filing and indexing.
Cost vs. human wageclaude-sonnet-53/5Automated archiving software reduces labor cost substantially, but validation, compliance checks, and integration with lab information systems still require technician time, keeping costs roughly comparable in many settings.
Technical feasibility todayclaude-haiku-4-5-202510014/5Mature enterprise document management and archival systems (e.g., Hyland OnBase, M-Files, hospital EMR systems) reliably perform this function in production across healthcare organizations, though integration with specific regulatory schemas may require some configuration.
Technical feasibility todayclaude-sonnet-53/5Document management systems with AI-assisted tagging, OCR, and retention scheduling exist and are deployed in labs and healthcare settings, but full end-to-end compliant archiving of cytogenetic case materials with images/slides typically still needs human verification.

Arrange and attach chromosomes in numbered pairs on karyotype charts, using standard genetics laboratory practices and nomenclature, to identify normal or abnormal chromosomes.

35

CI 25–45 · exposure 38 · augmentation 63 · importance 5.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of AI-assisted karyotyping in clinical laboratories has been slow and cautious, remaining largely at the pilot stage. Most clinical cytogenetics labs still rely on manual or semi-manual workflows due to regulatory constraints, quality assurance demands, and the high cost of error in a diagnostic context.
Sector adoption velocityclaude-sonnet-53/5Clinical laboratory sector has moderate digitization with semi-automated karyotyping tools in common use, but full AI-driven interpretation remains a slower-adopting, tightly regulated niche.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist by pre-sorting chromosome images, flagging anomalies, or automating initial segmentation, reducing technologist manual effort. However, the human must still verify pairing, apply nomenclature rules, and validate clinical accuracy, limiting the productivity gain to a moderate level of assistance rather than transformative augmentation.
Augmentation potentialclaude-sonnet-54/5Automated image analysis substantially speeds up chromosome sorting and pairing, letting technologists focus on verification and abnormality detection, meaningfully boosting throughput.
Task automatabilityclaude-haiku-4-5-202510012/5While image analysis and chromosome detection can be automated, the task requires careful visual matching, spatial arrangement, and nomenclature classification that demands human-level pattern recognition and judgment. Current AI cannot reliably perform the full end-to-end task of arranging, attaching, and verifying karyotype accuracy without substantial human oversight, falling well short of the 50% time-saving threshold.
Task automatabilityclaude-sonnet-53/5Image-based karyotyping software already automates chromosome pairing and arrangement using pattern recognition, but abnormal or ambiguous cases still require expert human verification, limiting full end-to-end automation.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical cytogenetics is highly regulated; karyotype results directly inform medical diagnosis and treatment decisions, creating strict liability and accuracy requirements. Healthcare organizations typically require human sign-off and credentialing, and regulatory frameworks (CLIA, CAP) impose oversight standards that prevent full automation without licensed professional validation.
Adoption barriersclaude-sonnet-54/5Clinical cytogenetic diagnoses typically require certified technologists and pathologist sign-off under CLIA/CAP regulations, creating strong liability and licensing barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Current AI chromosome analysis tools require expensive specialized hardware, sophisticated image processing pipelines, and ongoing human oversight to validate outputs. The all-in cost per karyotype likely exceeds the loaded wage of a trained cytogenetic technologist, especially when accounting for integration and clinical liability.
Cost vs. human wageclaude-sonnet-53/5Karyotyping software licenses and imaging hardware represent a substantial upfront and maintenance cost, but they reduce technologist time significantly, putting the cost roughly comparable to or somewhat below labor costs at scale.
Technical feasibility todayclaude-haiku-4-5-202510012/5Research systems and early-stage products exist for chromosome image segmentation and detection, but no mature production system reliably performs the complete karyotype arrangement, pairing, and nomenclature classification at the accuracy required for clinical use. Error rates remain too high for independent deployment without significant human verification.
Technical feasibility todayclaude-sonnet-53/5Automated karyotyping systems (e.g., Ikaros, CytoVision) are deployed in many cytogenetics labs and reliably handle routine arrangement, but accuracy drops for complex abnormalities requiring technologist correction.

Determine optimal time sequences and methods for manual or robotic cell harvests.

34

CI 7–60 · exposure 41 · augmentation 50 · importance 4.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Cytogenetics labs are relatively small, specialized, and slow to adopt novel automation outside of large hospital networks and commercial cytogenetics centers. Protocol optimization remains largely manual and conservative, with adoption of AI-assisted methods still in pilot phases.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory sciences adopt automation slowly due to regulatory validation requirements and specialized biological workflows, with robotic harvesting existing but decision-making automation lagging.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can substantially assist technologists by recommending harvest timing based on real-time microscopy data, suggesting robotic vs. manual methods, and flagging protocol deviations—enabling faster, more consistent decisions while the technologist retains oversight and judgment on final parameters.
Augmentation potentialclaude-sonnet-52/5Lab information systems and scheduling tools can support tracking of culture timelines, offering modest assistance, but no AI system meaningfully augments the core judgment involved in timing decisions.
Task automatabilityclaude-haiku-4-5-202510015/5Determining optimal harvest timing and methods is primarily a pattern-recognition and procedural-optimization task. AI systems can analyze historical cell culture data, literature on harvest protocols, and growth curves to recommend sequences and methods that meet quality thresholds, achieving >50% time savings by automating protocol selection and parameter optimization.
Task automatabilityclaude-sonnet-51/5This requires real-time judgment based on cell culture growth, morphology, and biological variability that current AI cannot observe or reason about end-to-end; no off-the-shelf system performs this task.a
Adoption barriersclaude-haiku-4-5-202510014/5Clinical and regulated laboratory settings require validated, documented protocols and technologist sign-off on critical parameters like harvest timing to ensure quality and compliance with CLIA/CAP standards. Regulatory and quality assurance requirements create material friction to full automation.
Adoption barriersclaude-sonnet-54/5Clinical cytogenetics work is subject to lab accreditation, CLIA-type regulations, and quality standards requiring qualified technologists to make and document harvest timing decisions, creating strong procedural and liability barriers.
Cost vs. human wageclaude-haiku-4-5-202510013/5Integration costs (protocol development, API coupling with lab information systems, validation) and ongoing curation are substantial, and the per-task inference cost must be amortized across many harvest runs. All-in costs are comparable to a technologist's labor for routine optimization work.
Cost vs. human wageclaude-sonnet-51/5There is no viable AI substitute performing this specific decision task, so cost comparison favors the human technologist who integrates visual and procedural expertise cheaply relative to any custom AI/robotic system build.
Technical feasibility todayclaude-haiku-4-5-202510013/5Laboratory automation software and AI-assisted protocol design tools exist in research and some clinical settings, but they typically require significant domain input and manual validation. Few deployed systems autonomously determine and execute optimal harvest sequences without technologist oversight across diverse cell types and conditions.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product determines cell harvest timing/methods in cytogenetics labs; this remains a specialized technologist judgment task supported at most by lab protocols and scheduling software.

Communicate to responsible parties unacceptable specimens and suggest remediation for future submissions.

28

CI 25–30 · exposure 25 · augmentation 50 · importance 4.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical cytogenetics remains a specialized, regulated domain with slower AI adoption. Most labs have not yet deployed autonomous specimen-rejection systems; adoption is in early pilot phases in well-resourced academic centers, not yet widespread in production across hospital and reference laboratory networks.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory settings are cautious adopters of AI for judgment-based, regulatory-adjacent communications, with slower uptake compared to purely administrative sectors.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can usefully assist technologists by flagging potential specimen defects in images, highlighting image quality issues, and prompting documentation of remediation suggestions, thereby reducing review time and improving consistency. However, the human technologist must retain final authority over acceptance/rejection and communication due to clinical judgment and regulatory requirements.
Augmentation potentialclaude-sonnet-53/5AI can help draft clear, consistent messages to submitters and suggest standard remediation language based on identified specimen issues, improving efficiency while the technologist retains judgment and responsibility.
Task automatabilityclaude-haiku-4-5-202510012/5Identifying unacceptable specimens requires visual and technical expertise that current AI can partially support through image analysis, but communicating findings to responsible parties and suggesting context-specific remediation requires human judgment about laboratory standards, clinical significance, and organizational relationships. AI could flag potential issues but cannot reliably handle the full end-to-end task of assessment and actionable communication.
Task automatabilityclaude-sonnet-52/5This requires domain judgment about specimen quality, understanding of lab-specific causes of rejection, and interpersonal communication tailored to the recipient, which AI can support but not fully replace end-to-end today.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical laboratory operations are regulated by CLIA and CAP, which mandate qualified personnel (licensed technologists) to certify specimen quality and communicate clinical findings. Liability for missed or mischaracterized specimens is substantial, and submitting physicians expect communication from qualified professionals, creating both regulatory and professional practice barriers.
Adoption barriersclaude-sonnet-53/5While not strictly licensed sign-off, this communication carries clinical and liability implications (affecting patient diagnosis), and organizational norms require a qualified professional to make and convey the assessment.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI-powered image analysis tools exist but require significant integration, validation in the clinical workflow, and human oversight to handle exceptions and communication. The all-in cost of deploying and maintaining such systems plus required human review is not substantially cheaper than paying a trained cytogenetic technologist for this specialized task.
Cost vs. human wageclaude-sonnet-52/5Because a trained technologist must still assess specimen quality and interface with clinical staff, AI can only reduce drafting time for messages, not replace the judgment and accountability, keeping cost savings modest.
Technical feasibility todayclaude-haiku-4-5-202510012/5While AI systems can assist in specimen image analysis and flagging defects, no deployed product reliably performs the complete task of independent specimen rejection and remediation communication in clinical cytogenetics settings. Clinical labs still require human technologists to make final determinations and communicate with submitting physicians, as quality judgments carry liability.
Technical feasibility todayclaude-sonnet-52/5No deployed lab-information systems autonomously identify unacceptable specimens and independently communicate remediation guidance to clinicians; this remains a human-driven QA/communication process with only drafting-assist tools available.

Summarize test results and report to appropriate authorities.

25

CI 25–25 · exposure 25 · augmentation 63 · importance 4.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical laboratory automation is advancing, but adoption of autonomous reporting—without human sign-off—remains minimal and slow. Laboratories are conservative, highly regulated, and currently prioritize human-verified reporting over end-to-end automation, making this a laggard sector for full task displacement.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory settings are cautious and slow adopters of AI for diagnostic reporting due to regulatory scrutiny and liability concerns, with pilots more common than production use.
Augmentation potentialclaude-haiku-4-5-202510014/5AI significantly assists cytogenetic technologists by automating data organization, generating draft summaries, flagging abnormal findings, and formatting reports. These augmentations measurably increase technologist productivity while the technologist retains interpretive control and certification responsibility.
Augmentation potentialclaude-sonnet-53/5AI can help draft standardized report language, flag anomalies for review, and speed up documentation, meaningfully assisting technologists while they retain final interpretive responsibility.
Task automatabilityclaude-haiku-4-5-202510012/5Summarizing cytogenetic test results requires interpreting complex genetic data and clinical context, which current AI can partially support through template-driven reporting and data extraction. However, end-to-end automation falls short of the 50% time-saving threshold because the task demands clinical judgment, quality assurance checks, and accountability that a technologist must verify and sign off on.
Task automatabilityclaude-sonnet-52/5Summarizing cytogenetic findings requires interpreting karyotype/FISH results with domain-specific judgment before reporting, which current general AI cannot reliably do end-to-end without heavy human verification., though drafting boilerplate report sections can be automated.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory barriers are substantial: cytogenetic reports typically require a licensed technologist or supervising physician to interpret and certify results before release. Clinical laboratories operate under CLIA and other regulations that mandate human professional accountability for reported findings, creating a hard licensing and liability barrier to full automation.
Adoption barriersclaude-sonnet-54/5Cytogenetic reports often require certified/licensed technologist or pathologist sign-off due to clinical and regulatory (CLIA/CAP) requirements, creating strong barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI assistance for reporting infrastructure (templates, formatting) is inexpensive, but the cost of integrating it with laboratory information systems, ensuring compliance validation, and maintaining human review is comparable to or exceeds the marginal labor cost saved by partial automation.
Cost vs. human wageclaude-sonnet-52/5AI drafting tools may reduce time slightly, but the need for expert verification and low error tolerance keeps oversight costs high relative to the wage of a specialized technologist.
Technical feasibility todayclaude-haiku-4-5-202510012/5Tools exist to assist with data aggregation and report templating, but no deployed AI system reliably performs end-to-end cytogenetic result summarization and reporting in production without human oversight. Existing products handle fragments (e.g., data extraction) but not the full clinical-legal accountability loop.
Technical feasibility todayclaude-sonnet-52/5Some lab information systems offer templated reporting and NLP-assisted summarization, but no widely deployed product autonomously generates and finalizes cytogenetic reports without technologist review.

Identify appropriate methods of specimen collection, preservation, or transport.

25

CI 25–25 · exposure 25 · augmentation 50 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical cytogenetics labs operate in a heavily regulated, conservative sector with slow digital transformation and strong adherence to validated manual workflows; adoption of AI for specimen handling decisions is minimal and pilot-stage at best.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory settings adopt AI slowly due to regulatory scrutiny, validation requirements, and safety-critical nature of specimen handling decisions.
Augmentation potentialclaude-haiku-4-5-202510013/5AI could provide useful assistance by summarizing specimen type-specific collection and transport requirements, flagging incompatible collection tubes, or suggesting optimal preservation methods based on analysis type, helping technologists avoid manual protocol lookup and reducing errors in method selection.
Augmentation potentialclaude-sonnet-53/5AI can help by providing quick reference to protocols, decision trees, or best practices for specimen handling, improving consistency and training but not replacing judgment.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can suggest specimen collection methods based on established protocols and cell type, the task requires domain-specific knowledge of preservation conditions, temperature requirements, and transport logistics that vary significantly by specimen type. AI could assist in protocol selection but cannot autonomously perform the physical selection and validation that this task entails in a clinical setting.
Task automatabilityclaude-sonnet-52/5This requires clinical judgment based on specimen type, test ordered, and institutional protocols, which AI can inform but not reliably decide end-to-end without human verification of biological samples and lab-specific constraints.:
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory frameworks (CLIA, CAP) require that specimen handling protocols be performed under the direct oversight of a licensed technologist or supervisor, and clinical laboratories mandate documented accountability for specimen integrity, creating legal and operational barriers to full automation.
Adoption barriersclaude-sonnet-54/5Clinical lab work is subject to accreditation (CLIA/CAP) standards requiring qualified personnel to make specimen handling decisions, creating strong regulatory and liability barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI systems capable of assisting with protocol lookup and selection would involve development and integration costs that are unlikely to be orders of magnitude cheaper than the technologist time saved, since the task is already rapid for trained personnel and requires human verification regardless.
Cost vs. human wageclaude-sonnet-52/5Human technologists with domain training are needed regardless, and integrating AI decision support adds cost without eliminating the need for skilled oversight, so savings are marginal.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed clinical AI systems autonomously identify and execute specimen collection method selection in production cytogenetic labs. While training algorithms can encode protocols, real systems require human cytogenetic technologists to verify suitability for the specific specimen and clinical context, making autonomous deployment impractical.
Technical feasibility todayclaude-sonnet-52/5No deployed product autonomously selects specimen collection/preservation/transport methods in cytogenetics labs; at best AI provides reference lookup or protocol assistance.

Examine chromosomes found in biological specimens to detect abnormalities.

25

CI 20–30 · exposure 30 · augmentation 75 · importance 5.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical labs are adopting AI-assisted screening tools, but adoption remains selective and primarily as decision-support rather than replacement. Regulatory caution, specialist workforce inertia, and the critical nature of accuracy have slowed deep penetration compared to less regulated sectors.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts AI cautiously due to regulatory validation requirements, with automated karyotyping tools deployed only in limited pilot or assistive capacities.
Augmentation potentialclaude-haiku-4-5-202510014/5AI-powered image analysis and chromosome segmentation tools meaningfully assist technologists by automating routine image preparation, flagging suspected abnormalities, and accelerating review, allowing humans to focus validation and complex interpretation. This augmentation is actively deployed and raises technologist productivity.
Augmentation potentialclaude-sonnet-54/5AI-based image analysis and pattern recognition tools meaningfully speed up chromosome counting, pairing, and flagging suspected abnormalities for technologist review, improving throughput and consistency.
Task automatabilityclaude-haiku-4-5-202510012/5AI can assist in image analysis and flag potential chromosome abnormalities in karyotype images, but the task requires nuanced interpretation of complex visual patterns, assessment of clinical significance, and integration with patient context that current systems handle inconsistently. End-to-end automation at 50% time savings with equal quality remains unreliable.
Task automatabilityclaude-sonnet-52/5AI image analysis can assist in karyotyping and detecting chromosomal abnormalities, but the full diagnostic task including specimen preparation, quality assessment, and clinical interpretation still requires substantial human expertise beyond current automation thresholds.
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetic analysis is regulated under CLIA and other clinical laboratory standards that typically require a licensed clinical laboratory technologist to perform and validate results. The high cost of errors (missed diagnoses affecting patient care) and legal/regulatory requirements for credentialed human sign-off create strong barriers to unsupervised automation.
Adoption barriersclaude-sonnet-55/5Cytogenetic diagnosis is a regulated clinical laboratory function requiring certified technologists and often physician sign-off under CLIA and similar regulatory frameworks, making full automation legally restricted.
Cost vs. human wageclaude-haiku-4-5-202510012/5Current AI imaging tools and software require licensing, integration into lab workflows, infrastructure, and ongoing human validation; the all-in cost is comparable to or exceeds a technologist's wage when accounting for oversight, error correction, and liability.
Cost vs. human wageclaude-sonnet-52/5Specialized cytogenetic AI imaging systems require significant capital investment, integration with lab workflows, and mandatory human verification, keeping costs comparable to or only modestly below skilled technologist labor.
Technical feasibility todayclaude-haiku-4-5-202510013/5Computer-aided detection systems and image analysis tools exist in clinical labs, but they require substantial human oversight, often produce false positives/negatives, and are typically used as screening aids rather than autonomous performers. No fully deployed product reliably replaces the technologist's judgment.
Technical feasibility todayclaude-sonnet-52/5Some FDA-cleared digital karyotyping and FISH analysis tools exist to assist technologists, but fully autonomous chromosome abnormality detection in clinical production settings is not yet standard practice.

Develop and implement training programs for trainees, medical students, resident physicians or post-doctoral fellows.

23

CI 16–30 · exposure 17 · augmentation 63 · importance 3.6/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Medical education institutions are conservative in adopting automation for training roles; they remain heavily dependent on human faculty credentialing and accreditation requirements. While AI supplements content creation, displacement of training program development itself is minimal in practice.
Sector adoption velocityclaude-sonnet-52/5Healthcare/clinical laboratory training environments have generally slow AI adoption for curriculum design and mentorship functions compared to purely digital sectors.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist by generating draft curricula, creating practice questions, organizing learning materials, and providing administrative support, which reduces instructor preparation time. However, the core task of live mentoring and assessment remains fundamentally human, limiting augmentation to partial productivity gains.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist in drafting training materials, creating assessments, summarizing literature, and generating case studies, significantly aiding the technologist who designs the program.
Task automatabilityclaude-haiku-4-5-202510011/5Training program development and implementation requires curriculum design, pedagogical judgment, adaptation to learner needs, and real-time mentoring of medical professionals. Current AI cannot autonomously create coherent, accredited training programs or deliver effective live instruction that meets the specialized needs of medical trainees.
Task automatabilityclaude-sonnet-52/5Developing curriculum content can be AI-assisted, but designing and delivering hands-on cytogenetic training involving lab technique, mentorship, and evaluation of trainee competency requires human judgment and physical demonstration that AI cannot perform end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Medical education for residents and fellows is heavily regulated by accrediting bodies (ACGME, etc.) that require human educators with specific credentials to design and oversee training. Liability for inadequate training and legal requirements for licensed professionals to certify competency create strong barriers to full automation.
Adoption barriersclaude-sonnet-53/5There's no strict licensing requirement to design training itself, but institutional accreditation standards, quality assurance, and need for expert oversight of medical trainee competency create moderate friction.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for content generation are inexpensive, but the human instructor's role—mentoring, real-time feedback, assessment, and program oversight—remains essential and costly. Meaningful cost replacement would be minimal since most of the value is human-delivered.
Cost vs. human wageclaude-sonnet-52/5AI can cheaply generate drafts of training materials, but the overall task still requires substantial paid expert time for oversight, hands-on instruction, and assessment, keeping cost savings modest.
Technical feasibility todayclaude-haiku-4-5-202510012/5While AI can generate training materials and answer questions, no deployed product reliably develops and implements full training programs for medical professionals end-to-end. Products exist for content generation but lack the pedagogical sophistication, accreditation awareness, and live instruction capability this role demands.
Technical feasibility todayclaude-sonnet-52/5AI tools (e.g., content generators, LMS platforms) exist to help draft training materials, but no deployed product manages full training program development and implementation for specialized medical/technical trainees reliably.

Count numbers of chromosomes and identify the structural abnormalities by viewing culture slides through microscopes, light microscopes, or photomicroscopes.

23

CI 20–25 · exposure 25 · augmentation 63 · importance 5.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of AI in cytogenetics has been slow and limited to research settings and optional screening tools. Most clinical laboratories still rely on human technologists, and regulatory burden plus the high cost of validation have prevented rapid uptake of fully automated systems in production pathology workflows.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts automation cautiously due to regulatory validation requirements, and digital karyotyping tools are used only in a minority of advanced labs.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can usefully assist technologists by pre-screening slides, highlighting abnormal regions, and automating preliminary chromosome segmentation, moderately raising their throughput. However, the core task of structural identification and final interpretation still requires human expertise and judgment, limiting augmentation to preparatory steps rather than full task transformation.
Augmentation potentialclaude-sonnet-54/5AI-assisted image analysis and pattern recognition tools meaningfully speed up chromosome counting and anomaly flagging, letting technologists focus on verification and complex cases.
Task automatabilityclaude-haiku-4-5-202510012/5While AI image analysis can detect some chromosomal abnormalities from microscopy images, current systems cannot reliably perform the full end-to-end task of chromosome counting and structural identification with the accuracy and consistency required for clinical cytogenetics. The task requires nuanced judgment about banding patterns, morphology, and subtle structural variations that still demand expert human oversight.
Task automatabilityclaude-sonnet-52/5While AI image analysis can assist in karyotyping and detecting numerical/structural abnormalities, full end-to-end replacement requires validated clinical-grade systems with human confirmation, so it doesn't yet meet the 50% time-savings-at-equal-quality bar broadly across labs.
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetic analysis results directly inform clinical diagnoses and treatment decisions; regulatory bodies (FDA, CAP, CLIA) require validated methodologies and human expert sign-off. Medical liability for misidentified chromosomal abnormalities is high, and professional licensing requirements for clinical cytogenetics create strong legal and organizational barriers to full automation.
Adoption barriersclaude-sonnet-55/5Clinical cytogenetic diagnoses require certified technologists and pathologist/geneticist sign-off under strict laboratory regulatory frameworks (e.g., CLIA, CAP), making full automation impossible without licensed human verification.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI image analysis systems for cytogenetics are expensive to develop and validate for clinical use, and they still require trained human technologists to review, verify, and make final calls. The total cost (including infrastructure, validation, and necessary human oversight) remains comparable to or higher than the cost of human technologists performing the task directly.
Cost vs. human wageclaude-sonnet-52/5Specialized cytogenetic imaging software and scanners require significant capital investment, and human oversight is mandatory, keeping costs comparable to or only modestly cheaper than skilled technologist labor.
Technical feasibility todayclaude-haiku-4-5-202510012/5Research-stage AI systems can segment and classify chromosomes from karyotype images, but deployed clinical products that reliably replace human cytogenetic technologists remain limited. While some AI-assisted tools exist for preliminary screening, they are not yet mature enough for independent production use in diagnostic cytogenetics without human validation.
Technical feasibility todayclaude-sonnet-52/5Some FDA-cleared or CE-marked digital karyotyping/image-analysis systems exist and are used to assist counting, but they still require technologist review and are not fully autonomous in most clinical settings.

Analyze chromosomes found in biological specimens to aid diagnoses and treatments for genetic diseases such as congenital disabilities, fertility problems, and hematological disorders.

23

CI 20–25 · exposure 25 · augmentation 75 · importance 4.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical laboratories have been slow to adopt autonomous AI; adoption remains in the pilot and proof-of-concept phase rather than deep production deployment. Regulatory caution, liability concerns, and entrenched manual workflows in most labs keep velocity low.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts automation cautiously due to regulatory validation requirements, with AI-assisted imaging tools only slowly integrated into cytogenetics workflows.
Augmentation potentialclaude-haiku-4-5-202510014/5AI excels at flagging candidate abnormalities, pre-screening karyotypes, and highlighting regions of interest for human review, substantially accelerating the technologist's review process. When kept in an assistive role, AI can meaningfully boost productivity and reduce cognitive load.
Augmentation potentialclaude-sonnet-54/5AI-assisted image analysis and automated karyotype software meaningfully speed up chromosome identification and anomaly flagging, improving technologist throughput and accuracy while humans retain final interpretive control.
Task automatabilityclaude-haiku-4-5-202510012/5While AI image recognition can assist in identifying some chromosomal abnormalities in karyotypes, the full task requires integrating specimen preparation, quality control, interpretation of edge cases, and clinical correlation—steps that currently demand human expertise and oversight. Current systems cannot reliably achieve the 50% time-saving threshold end-to-end.
Task automatabilityclaude-sonnet-52/5AI image analysis can assist with karyotyping and detecting some chromosomal abnormalities, but full diagnostic analysis integrating clinical context, rare anomalies, and quality judgment still requires trained technologists and pathologist sign-off.
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetic analysis is embedded in regulated clinical laboratory workflows (CLIA/CAP compliance), results inform medical diagnoses and treatment decisions, and liability for misclassification is substantial. Regulatory oversight and the requirement for human sign-off on diagnostic results create meaningful adoption barriers.
Adoption barriersclaude-sonnet-55/5Clinical cytogenetic diagnosis is heavily regulated (CLIA, CAP certification) and requires certified technologists and physician sign-off, creating strong licensing and liability barriers to automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI-assisted cytogenetics systems require significant infrastructure, integration, training, and ongoing oversight costs; the loaded cost per case often approaches or exceeds that of a trained technologist, especially when accounting for false positives and required human review.
Cost vs. human wageclaude-sonnet-52/5Specialized cytogenetic imaging systems and AI tools carry significant licensing, validation, and integration costs, and human oversight remains mandatory, so the cost advantage over trained technologists is modest.
Technical feasibility todayclaude-haiku-4-5-202510012/5Research prototypes exist for automated chromosome classification, but deployed clinical products remain limited and typically serve as assistive tools rather than autonomous performers. Clinical laboratories still rely heavily on manual review and expert judgment, with AI showing only narrow applicability in controlled settings.
Technical feasibility todayclaude-sonnet-52/5Some automated karyotyping software (e.g., digital imaging systems) is deployed in labs to assist with chromosome pairing/counting, but it is not fully autonomous and requires human verification for diagnostic reporting.

Develop, implement, and monitor quality control and quality assurance programs to ensure accurate and precise test performance and reports.

23

CI 20–25 · exposure 25 · augmentation 50 · importance 4.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical laboratories adopt AI cautiously due to regulatory requirements and the safety-critical nature of cytogenetic testing; adoption is limited to specific monitoring and analysis modules rather than end-to-end program development.
Sector adoption velocityclaude-sonnet-52/5Clinical cytogenetics labs are a specialized, highly regulated niche with slow AI adoption compared to fast-moving digital sectors, though some LIS/QC software adoption is occurring.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can augment technologists by automating routine QC data tracking, flagging anomalies, and generating reports, but the human must retain responsibility for interpreting findings and modifying programs based on results.
Augmentation potentialclaude-sonnet-53/5AI can help analyze QC trend data, flag anomalies, and draft documentation, providing meaningful assistance to technologists managing quality programs without replacing their oversight role.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist with data analysis and anomaly detection in QC/QA workflows, the task requires developing and implementing oversight programs that depend on domain expertise, regulatory knowledge, and organizational judgment that current AI systems cannot perform end-to-end at scale.
Task automatabilityclaude-sonnet-52/5Developing and implementing QA/QC programs requires clinical judgment, regulatory knowledge, and lab-specific decision-making that current AI cannot autonomously perform end-to-end, though it can assist with documentation and data analysis pieces.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical laboratory testing is heavily regulated (CLIA, CAP accreditation) and typically requires licensed personnel to develop, sign off on, and maintain QC/QA programs, creating substantial legal and compliance barriers to full automation.
Adoption barriersclaude-sonnet-55/5Clinical laboratory QA/QC programs fall under strict regulatory frameworks (CLIA, CAP) requiring certified personnel to design, sign off on, and be accountable for quality systems, making full automation legally infeasible.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI systems for QC monitoring have meaningful setup and integration costs plus ongoing oversight by qualified technologists, making the total cost comparable to or higher than human-driven program development and management.
Cost vs. human wageclaude-sonnet-52/5Given the need for specialized technologist expertise, regulatory compliance, and validation, AI tools would supplement rather than replace labor, so cost savings are modest rather than order-of-magnitude.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably develops and implements entire QC/QA programs autonomously; existing tools support monitoring and analysis but require significant human expertise in cytogenetics and regulatory compliance to establish and maintain programs.
Technical feasibility todayclaude-sonnet-52/5No deployed product autonomously designs and monitors cytogenetic QA/QC programs; existing lab informatics tools support tracking but require expert configuration and oversight throughout.

Recognize and report abnormalities in the color, size, shape, composition, or pattern of cells.

23

CI 20–25 · exposure 25 · augmentation 63 · importance 4.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical and diagnostic laboratories adopt AI tools slowly due to regulatory oversight, validation requirements, and conservative quality culture. Adoption remains largely in pilots and research settings; production deployment of autonomous AI cytogenetics is minimal across the sector.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory diagnostics is a highly regulated, cautious sector; while image analysis AI is emerging, deep production adoption for cytogenetic abnormality detection remains limited and slow-moving.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can meaningfully assist technologists by flagging suspect cells, highlighting regions of interest, and pre-screening slides to improve throughput and reduce technologist fatigue. Computer-aided detection tools can enhance human accuracy and speed while the technologist retains interpretive responsibility.
Augmentation potentialclaude-sonnet-53/5AI-assisted image analysis and pattern recognition tools can help flag candidate abnormalities and speed up review, though technologists still perform confirmatory judgment and reporting.
Task automatabilityclaude-haiku-4-5-202510012/5Current AI can detect some morphological abnormalities in cell images with reasonable accuracy, but the task requires nuanced interpretation of subtle variations in color, size, shape, and pattern that often demand expert judgment. While partial automation of flagging candidates is possible, reaching 50% time savings at equal quality across diverse cytogenetic specimens remains unproven in production.
Task automatabilityclaude-sonnet-52/5Detecting chromosomal abnormalities via karyotyping and FISH requires trained morphological judgment and correlation with clinical context; AI image analysis can assist but cannot yet fully replace the diagnostic reporting end-to-end at equal quality across all case types.
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetic reporting is regulated under CLIA and other clinical laboratory standards; abnormality findings often trigger medical decisions requiring human sign-off and interpretation in clinical context. The requirement for licensed technologist or certified professional to validate and report results creates substantial legal and liability barriers to full automation.
Adoption barriersclaude-sonnet-55/5Clinical cytogenetic reporting is subject to strict regulatory (CLIA/CAP) and licensure requirements, with a certified technologist or pathologist required to interpret and sign off on results.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI inference costs for microscopy image analysis are modest, but the task requires high-quality imaging hardware, integration with laboratory workflows, and expert oversight to validate findings. All-in costs remain comparable to or exceed the loaded wage of a technologist, especially when accounting for liability and rework.
Cost vs. human wageclaude-sonnet-52/5Specialized cytogenetic AI tools require costly validation, integration with lab equipment, and human oversight for legal/clinical sign-off, making all-in AI costs not dramatically cheaper than technologist labor yet.
Technical feasibility todayclaude-haiku-4-5-202510012/5Image analysis tools and machine learning models for cytology exist in research and some clinical pilots, but no mature, widely deployed product reliably performs end-to-end cytogenetic abnormality recognition at the standard expected in certified labs. Error rates and false negatives remain clinically unacceptable for independent deployment.
Technical feasibility todayclaude-sonnet-52/5Some digital karyotyping software and AI-assisted image analysis tools exist in research/clinical pilot settings, but widespread production reliance on AI for definitive abnormality reporting is not standard practice.

Select appropriate culturing system or procedure based on specimen type and reason for referral.

21

CI 18–25 · exposure 20 · augmentation 50 · importance 4.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Clinical laboratory automation, while growing, remains slow and conservative; adoption of autonomous decision-making in specimen handling lags far behind other sectors due to regulatory complexity, quality assurance demands, and the safety-critical nature of the work.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory sciences, especially specialized cytogenetics, show slow AI adoption for core technical decision-making compared to information-sector professions.
Augmentation potentialclaude-haiku-4-5-202510013/5AI could assist technologists by flagging relevant culturing options, summarizing specimen data, or highlighting unusual referral patterns, moderately raising throughput and reducing cognitive load while the technologist retains final selection authority and responsibility.
Augmentation potentialclaude-sonnet-53/5AI decision-support tools or reference databases could help technologists quickly identify recommended protocols for specimen types, aiding but not replacing their judgment.
Task automatabilityclaude-haiku-4-5-202510012/5While AI could assist in matching specimen types to culturing procedures via rule-based logic or decision trees, the selection requires domain expertise, contextual judgment about specimen quality and referral subtleties, and real-time adaptation that current systems cannot reliably perform end-to-end without human oversight, yielding insufficient time savings at equal quality.
Task automatabilityclaude-sonnet-52/5This requires specialized biological judgment integrating specimen type, referral reason, and lab protocols; current AI lacks the physical and contextual integration needed to make this decision reliably end-to-end.5performperforms this decision autonomously today.
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetics is a regulated clinical laboratory domain (CLIA/CAP certification applies); substantive errors in culture selection directly impact diagnostic accuracy and patient outcomes, creating high liability costs and regulatory scrutiny that restrict autonomous automation and require human sign-off on critical decisions.
Adoption barriersclaude-sonnet-54/5Clinical lab work is subject to CLIA/CAP regulations and requires certified technologists; errors in culture selection can compromise diagnosis, creating strong liability and licensing barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5Implementing a validated AI-based selection system with necessary integration, validation, and ongoing oversight would require significant upfront cost and expert review, likely matching or exceeding the cost of a trained technologist making these selections.
Cost vs. human wageclaude-sonnet-52/5Even if AI could suggest a protocol, the cost of validating and integrating such a system into a regulated lab workflow would likely exceed near-term savings versus a trained technologist making this decision.
Technical feasibility todayclaude-haiku-4-5-202510012/5Decision-support tools exist in some lab information systems, but no deployed product reliably performs this selection autonomously in production; systems lack the nuanced interpretation of referral context and specimen variation that cytogenetic labs require, making error rates unacceptable for routine automation.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product selects cytogenetic culturing protocols in clinical labs; this remains a specialized technologist judgment task without commercial automation.

Apply prepared specimen and control to appropriate grid, run instrumentation, and produce analyzable results.

21

CI 16–25 · exposure 20 · augmentation 38 · importance 4.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of automation in cytogenetics is slow and limited to large, well-resourced medical centers and reference labs. Most smaller clinical labs continue manual or semi-automated workflows due to cost, regulatory friction, and the technical complexity of implementation.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory sectors adopt automation for instrumentation but physical specimen handling and grid preparation remain manual, with slow uptake of full automation in cytogenetics workflows.
Augmentation potentialclaude-haiku-4-5-202510013/5Image analysis software and automated scanning can assist technologists by flagging potential anomalies and reducing manual review time, though the human must still interpret findings and validate results for clinical reporting.
Augmentation potentialclaude-sonnet-52/5AI can assist with downstream image analysis or data interpretation once results are produced, but offers little support for the physical specimen application and instrument-running steps themselves.
Task automatabilityclaude-haiku-4-5-202510012/5While instrumentation can run and produce raw data automatically, the specimen preparation, grid application, and quality-control judgment to ensure 'analyzable results' require human expertise and manual dexterity that current AI cannot fully replicate end-to-end. Partial automation of data processing is feasible, but the critical pre-analytical and verification steps remain human-dependent.
Task automatabilityclaude-sonnet-52/5This involves physical manipulation of biological specimens and operation of laboratory instrumentation, which requires manual dexterity and real-world sensorimotor skills current AI cannot replicate end-to-end.the analysis output stage could be assisted but the physical loading/running steps resist automation.
Adoption barriersclaude-haiku-4-5-202510014/5CLIA certification, quality-assurance requirements, and regulatory oversight of laboratory processes create legal and compliance barriers. A licensed technologist must validate procedures and sign off on results, limiting full automation and substitution.
Adoption barriersclaude-sonnet-54/5Cytogenetic testing is subject to clinical lab regulations (e.g., CLIA) requiring certified technologists to perform and verify specimen processing, creating strong licensing and liability barriers to automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Automated instrumentation is expensive (capital, integration, ongoing calibration costs) relative to a technologist's labor, especially in lower-volume labs. Break-even is possible only in high-throughput settings with substantial infrastructure investment.
Cost vs. human wageclaude-sonnet-51/5There is no AI substitute for the physical specimen-loading task, so the relevant cost comparison is between a technologist's wage and non-existent AI alternative, making AI effectively unusable and not cost-competitive.
Technical feasibility todayclaude-haiku-4-5-202510012/5Robotic sample handlers and automated slide scanners exist in research and some clinical labs, but they require significant setup, maintenance, and human oversight. No fully autonomous product reliably performs the complete specimen application, control placement, and result validation without technologist intervention.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical specimen handling and grid loading; this remains a manual laboratory task performed by trained technologists with automated instruments, not AI-driven robotic systems.

Extract, measure, dilute as appropriate, label, and prepare DNA for array analysis.

21

CI 16–25 · exposure 20 · augmentation 25 · importance 4.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Most cytogenetics laboratories are smaller, hospital-based, or specialized clinical settings with slower digital transformation. Adoption of automation is selective and driven by high-volume centers; the sector overall lags technology adoption compared to finance or IT.
Sector adoption velocityclaude-sonnet-52/5Clinical cytogenetics labs adopt automation slowly due to regulatory validation requirements, cost of specialized equipment, and the physical nature of the work, unlike faster-adopting information-based sectors.
Augmentation potentialclaude-haiku-4-5-202510012/5AI offers minimal assistance in DNA extraction and preparation; visual inspection, judgment on sample quality, and hands-on technique adjustments remain human-dependent. Software for tracking and labeling exists but does not meaningfully transform technologist productivity on the core task.
Augmentation potentialclaude-sonnet-52/5AI can assist with data recording, LIMS integration, or downstream array data interpretation, but offers minimal support for the physical extraction and preparation steps themselves.
Task automatabilityclaude-haiku-4-5-202510012/5While some components (measuring, diluting, labeling) involve routine liquid handling that could be partially automated, the extraction step requires skilled judgment and manual dexterity with biological samples. End-to-end automation with 50% time savings at equal quality remains challenging without specialized robotics and significant setup.
Task automatabilityclaude-sonnet-52/5This is a hands-on wet-lab procedure involving physical sample manipulation, pipetting, and instrument operation that current AI systems cannot perform end-to-end; only data-analysis-adjacent portions could be assisted.rate
Adoption barriersclaude-haiku-4-5-202510014/5Clinical cytogenetics often operates in regulated environments (CLIA, CAP) where validation and quality control are stringent; liability for sample handling errors is high, and human sign-off on DNA quality and preparation is typically required before array analysis.
Adoption barriersclaude-sonnet-54/5Clinical lab testing is subject to CLIA/CAP regulations requiring qualified technologists to perform and verify sample processing, creating significant regulatory and liability barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Specialized laboratory automation and robotics for DNA preparation are capital-intensive and require ongoing maintenance and validation, making per-sample costs comparable to or higher than a trained technologist's labor, especially at typical laboratory volumes.
Cost vs. human wageclaude-sonnet-51/5AI software cannot substitute for the physical lab work at all, so cost comparison favors the human technician; any automation would require expensive specialized lab robotics, not generally available AI.
Technical feasibility todayclaude-haiku-4-5-202510012/5Liquid handlers and some laboratory automation exist, but they require extensive calibration and validation for cytogenetic work, and extraction quality remains operator-dependent. No mature, off-the-shelf system reliably performs the full pipeline without specialized adaptation and human oversight.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical DNA extraction, dilution, and labeling; this remains a manual laboratory task requiring robotics/automation systems distinct from AI software, and such lab automation is not AI-driven in the relevant sense.

Evaluate appropriateness of received specimens for requested tests.

21

CI 16–25 · exposure 20 · augmentation 38 · importance 4.6/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical and diagnostic laboratories are moderate adopters of AI; while larger centers pilot automation, widespread production deployment of specimen-screening systems lags due to regulatory burden, validation timelines, and preference for human technologist oversight.
Sector adoption velocityclaude-sonnet-52/5Clinical cytogenetics labs are slow to adopt AI for hands-on specimen handling and quality judgment, though some digital pathology and LIS tools are emerging.
Augmentation potentialclaude-haiku-4-5-202510013/5AI-assisted flagging of potential issues (contamination, insufficient volume, labeling anomalies) can support technologists' decision-making and speed routine screening, though the technologist must always retain final judgment on appropriateness.
Augmentation potentialclaude-sonnet-52/5AI can assist with flagging metadata mismatches or checklist compliance in requisitions, but core physical/biological specimen evaluation still relies on human expertise.
Task automatabilityclaude-haiku-4-5-202510012/5AI can assist in reviewing specimen metadata and comparing against test requirements, but evaluates appropriateness by recognizing patterns in specimen integrity, contamination, and labeling—tasks requiring domain expertise and visual/contextual judgment that current systems handle only with high false-positive rates and significant manual review.
Task automatabilityclaude-sonnet-52/5This requires integrating physical specimen quality assessment, clinical context, and laboratory protocols; current AI cannot reliably inspect physical samples or make holistic acceptability judgments end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical labs operate under strict CLIA/CAP certification and quality standards; any automated specimen triage introduces liability and must be validated and supervised by licensed personnel, creating hard regulatory and organizational friction against full substitution.
Adoption barriersclaude-sonnet-54/5Clinical lab testing is subject to CLIA and accreditation standards requiring qualified personnel to assess specimen adequacy, creating strong regulatory and liability barriers to automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Setup and validation of AI screening systems, plus mandatory technologist oversight and liability for errors, make all-in costs comparable to or exceed the wage of a technologist performing this task directly.
Cost vs. human wageclaude-sonnet-51/5There is no AI system performing this task at scale, so no meaningful cost comparison exists; a human technologist remains the only viable performer.
Technical feasibility todayclaude-haiku-4-5-202510012/5While image analysis and rule-based screening tools exist in research, no mature production system reliably evaluates specimen appropriateness across the full range of test types, specimen conditions, and rejection criteria with the precision required in clinical labs.
Technical feasibility todayclaude-sonnet-51/5No deployed product autonomously evaluates specimen appropriateness for cytogenetic testing; this remains a manual technologist judgment task in labs today.

Describe chromosome, FISH and aCGH analysis results in International System of Cytogenetic Nomenclature (ISCN) language.

20

CI 15–25 · exposure 20 · augmentation 50 · importance 4.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Cytogenetics is a specialized, low-volume clinical sector with strong regulatory and quality oversight; adoption of autonomous AI reporting remains pilot-stage, with most labs still using image enhancement as a supporting tool rather than replacing technologist-authored nomenclature.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts AI cautiously due to regulatory and validation requirements, with pilots for image analysis but slow deployment of autonomous reporting tools in cytogenetics.
Augmentation potentialclaude-haiku-4-5-202510013/5AI-powered image analysis and pattern detection can assist technologists by highlighting candidate abnormalities and suggesting preliminary classifications, reducing search time and cognitive load, but the technologist must retain judgment to finalize ISCN descriptions and validate all clinical findings.
Augmentation potentialclaude-sonnet-53/5AI-assisted image analysis and karyotyping software can help technologists identify abnormalities and draft preliminary notation, improving throughput while the technologist finalizes and validates results.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can recognize and classify chromosomal patterns from images with reasonable accuracy, ISCN nomenclature requires precise, standardized technical language for complex findings, multiple contingent rules, and expert judgment on ambiguous cases. Current AI systems cannot reliably generate full ISCN descriptions meeting laboratory reporting standards without substantial human oversight and correction.
Task automatabilityclaude-sonnet-52/5Generating accurate ISCN notation requires precise interpretation of karyotype images and molecular data; while AI can assist in drafting notation from structured findings, full end-to-end automation at equal quality is not yet reliable for diverse abnormal cases.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical cytogenetics is heavily regulated (CLIA, CAP) and requires licensed medical professionals to validate and sign-off on diagnostic reports; liability for misclassified chromosomal anomalies is high, and many labs have contractual and clinical-quality requirements that mandate human expert review before reporting results.
Adoption barriersclaude-sonnet-55/5Clinical cytogenetic reporting is tightly regulated (CLIA/CAP) and requires certified technologists/directors to verify and sign off on results, creating strong legal and liability barriers to automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Current AI-assisted systems require expensive specialized hardware (microscopy, digital scanners) and skilled human oversight to verify and correct outputs, making per-report costs comparable to or exceeding the wage cost of an experienced technologist performing the task independently.
Cost vs. human wageclaude-sonnet-52/5Specialized cytogenetic AI tools are not commoditized, and integration plus mandatory expert review costs partially offset any inference savings, keeping costs closer to comparable than dramatically cheaper.
Technical feasibility todayclaude-haiku-4-5-202510012/5Some image analysis tools for chromosome detection exist in research and early clinical settings, but no deployed product reliably generates complete, clinically validated ISCN reports end-to-end. Laboratory systems still require cytogeneticists to review and author the final nomenclature, as error rates and missing edge cases remain material.
Technical feasibility todayclaude-sonnet-51/5No widely deployed clinical product autonomously generates ISCN-compliant descriptions from raw cytogenetic images; existing image analysis software still requires technologist interpretation and manual notation entry.

Select or prepare specimens and media for cell cultures using aseptic techniques, knowledge of medium components, or cell nutritional requirements.

19

CI 14–25 · exposure 20 · augmentation 38 · importance 4.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical labs have adopted some automation for high-throughput, standardized steps, but adoption remains uneven and concentrated in large reference labs; most hospitals and smaller labs continue to rely on manual technologist work for specimen prep and culture media selection due to regulatory overhead and variability.
Sector adoption velocityclaude-sonnet-51/5Clinical cytogenetics labs are a physical, highly regulated, and slow-to-digitize sector with minimal AI-driven automation of manual wet-lab procedures.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can augment technologist work through image analysis to support specimen quality assessment, computational tools to optimize medium formulation, and knowledge systems to recommend protocols; however, the human must remain in control of aseptic handling and final decision-making.
Augmentation potentialclaude-sonnet-52/5AI can help with protocol lookup, documentation, or scheduling reminders about media components, but offers little direct assistance to the physical, hands-on task of aseptic specimen preparation.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist in decision logic for specimen selection and medium formulation via image analysis and protocol interpretation, the core tasks—physical specimen handling with aseptic technique and actual media preparation—require hands-on laboratory manipulation that current robotic systems cannot reliably perform end-to-end in diverse clinical or research contexts.
Task automatabilityclaude-sonnet-52/5This is a hands-on wet-lab task requiring physical manipulation of biological specimens under sterile conditions; current AI cannot physically prepare cultures, though it could assist in protocol selection or documentation.
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetic work operates under strict regulatory frameworks (CLIA, CAP accreditation) that require qualified personnel to oversee specimen handling and quality assurance; aseptic technique and contamination control are legally and clinically mandated, creating strong organizational and compliance barriers to full automation.
Adoption barriersclaude-sonnet-54/5Cytogenetic work is subject to clinical lab regulations (e.g., CLIA) requiring certified personnel to perform and document specimen handling, and errors in culture prep can compromise diagnostic accuracy, creating strong liability and credentialing barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5Specialized laboratory automation equipment and integration costs are typically high, and the task involves variable specimen types and conditions that limit reusable automation; human technologists performing this work remain cost-competitive for most contexts.
Cost vs. human wageclaude-sonnet-51/5There is no AI substitute for physical lab work, so any 'AI cost' would require robotic lab automation systems that are far more expensive than a technologist's wage for this task.
Technical feasibility todayclaude-haiku-4-5-202510012/5Specialized lab automation exists for specific, high-volume standardized protocols (e.g., DNA extraction), but deployed systems rarely handle the full spectrum of specimen selection, aseptic technique execution, and dynamic medium adjustment that this task entails, especially in smaller or research settings.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical aseptic specimen handling or cell culture preparation in production labs; this remains a manual laboratory skill requiring trained technologists.

Communicate test results or technical information to patients, physicians, family members, or researchers.

19

CI 18–20 · exposure 25 · augmentation 63 · importance 4.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Healthcare, particularly genetic counseling and patient communication, remains a laggard in AI automation due to regulatory constraints, liability concerns, and strong human-contact requirements. Production deployment of AI for autonomous patient communication about genetic results is minimal.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory and genetics fields are cautious adopters of AI for patient-facing communication due to regulatory and liability concerns, with pilots limited mostly to documentation support.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist technologists by drafting clear, jargon-reduced explanations of complex results or generating standardized educational materials about test procedures and significance. However, the personalized, interactive nature of actual patient communication limits transformative augmentation.
Augmentation potentialclaude-sonnet-54/5AI can help draft plain-language explanations, prepare summaries for physicians, or organize data for researcher communication, meaningfully aiding the technologist while they remain responsible for delivery.
Task automatabilityclaude-haiku-4-5-202510012/5AI cannot reliably handle the full task of communicating sensitive genetic test results, which requires understanding individual patient context, interpreting complex medical significance, and responding to emotional reactions. While AI could draft result summaries or educational materials, the personalized, context-aware communication and empathetic engagement required for patient-facing results fall outside current AI capabilities.
Task automatabilityclaude-sonnet-52/5Communicating cytogenetic test results requires interpreting complex genetic data, contextualizing for the audience, and handling emotionally sensitive conversations, which AI cannot reliably perform end-to-end today.dominant
Adoption barriersclaude-haiku-4-5-202510015/5Regulatory and legal barriers are substantial: healthcare licensing, HIPAA compliance, informed consent requirements, and liability for miscommunication of genetic information mean that authorized healthcare professionals must oversee or directly perform patient communication. Malpractice risk and regulatory mandates create hard barriers to substitution.
Adoption barriersclaude-sonnet-55/5Communicating diagnostic genetic results is tightly regulated, typically requires licensed personnel (technologists, genetic counselors, physicians), and carries significant liability and human-contact requirements.
Cost vs. human wageclaude-haiku-4-5-202510012/5Even if AI systems could perform aspects of this task, the need for human oversight, error checking, and emotional labor mean the all-in cost (AI + oversight + integration) remains comparable to or higher than direct technologist communication.
Cost vs. human wageclaude-sonnet-52/5While AI drafting tools are cheap, the need for expert review, liability management, and human delivery of sensitive results means overall cost savings versus a technologist/genetic counselor are limited.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably performs patient-facing genetic result communication end-to-end in production healthcare settings. Chatbots can provide general information but cannot replace the clinical judgment and personal interaction required for explaining cytogenetic findings to patients and physicians.
Technical feasibility todayclaude-sonnet-52/5AI chatbots can draft summaries or explain terminology, but no deployed product autonomously communicates diagnostic cytogenetic results to patients or physicians in clinical practice.

Harvest cell cultures using substances such as mitotic arrestants, cell releasing agents, and cell fixatives.

15

CI 5–25 · exposure 13 · augmentation 38 · importance 4.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical and research cytogenetics labs remain relatively small, specialized, and slow to adopt unproven automation. Adoption is concentrated in high-throughput centers; most labs still rely on manual technician workflow due to capital constraints and regulatory validation burdens.
Sector adoption velocityclaude-sonnet-51/5Clinical cytogenetics labs are highly specialized, low-digitization environments focused on physical sample processing, showing minimal AI adoption for hands-on procedures.
Augmentation potentialclaude-haiku-4-5-202510013/5Automated liquid handlers and robotic arms can assist technicians by handling repetitive reagent addition and incubation scheduling, reducing labor on routine steps while the technician monitors culture quality and makes go/no-go decisions. This represents meaningful but incremental productivity gain rather than transformative augmentation.
Augmentation potentialclaude-sonnet-52/5AI could assist with protocol documentation, timing reminders, or quality tracking, but offers minimal help with the core physical harvesting steps.
Task automatabilityclaude-haiku-4-5-202510012/5Cell culture harvesting involves precise physical handling of biological materials, temperature control, chemical reagent selection, and observation of cell morphology—tasks requiring dexterous manipulation and real-time visual judgment that current AI cannot perform end-to-end. While some liquid-handling steps could be partially automated with specialized robotics, the full workflow including substrate preparation, chemical application timing, and quality assessment remains heavily manual.
Task automatabilityclaude-sonnet-51/5This is a hands-on wet-lab procedure requiring physical manipulation of cell cultures, precise timing, and reagent handling that current AI systems cannot physically perform.itorial.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory barriers are substantial: FDA guidance, CLIA compliance, and laboratory accreditation require validated, documented procedures and often human sign-off on cell culture quality and integrity. Liability for contamination or culture failure creates organizational friction against full automation without extensive validation.
Adoption barriersclaude-sonnet-54/5Cytogenetic testing is subject to clinical lab regulations (CLIA/CAP) requiring qualified technologists to perform and verify procedures, creating strong regulatory and liability barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5Specialized laboratory robotics and integration costs are high; cytogenetic technologists' fully-loaded wage (~$50–70k annually) spread across many daily harvests yields low per-task cost. Automation equipment and validation would exceed the cost savings for most labs, especially those with moderate throughput.
Cost vs. human wageclaude-sonnet-51/5AI cannot perform this physical task at all, so there is no viable cost comparison—human labor with lab equipment remains the only option.
Technical feasibility todayclaude-haiku-4-5-202510012/5Liquid-handling robots exist for narrow aspects (reagent dispensing), but no deployed AI system reliably performs the complete harvest workflow autonomously. Current systems lack the integrated vision, dexterity, and adaptive decision-making needed to monitor culture quality, recognize harvest readiness, and manage the chemical sequence safely in a production laboratory setting.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical cell culture harvesting; this remains entirely a manual laboratory technique requiring human dexterity and judgment.

Prepare slides of cell cultures following standard procedures.

15

CI 5–25 · exposure 13 · augmentation 38 · importance 4.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of slide-prep automation remains limited to large, well-resourced labs and commercial cytogenetics centers; most hospital and diagnostic labs still rely on manual preparation due to capital constraints, regulatory friction, and workflow integration challenges.
Sector adoption velocityclaude-sonnet-51/5Clinical cytogenetics labs are a low-digitization, physical-task-heavy sector with slow adoption of AI/robotics for wet-lab procedures.
Augmentation potentialclaude-haiku-4-5-202510013/5AI-assisted image analysis and quality checking (post-preparation) can help technologists prioritize slides and flag outliers, improving productivity modestly. Automated slide staining systems also reduce physical burden, though the core skill of preparation remains human-driven.
Augmentation potentialclaude-sonnet-52/5AI can assist with protocol documentation, scheduling, or quality tracking, but offers minimal direct enhancement to the physical slide preparation process itself.
Task automatabilityclaude-haiku-4-5-202510012/5Preparing slides involves hands-on micromanipulation of cell cultures, staining, and mounting—physical tasks that current AI cannot execute end-to-end. While image analysis of prepared slides is automatable, the wet-lab preparation itself remains beyond robotic deployment in most settings.
Task automatabilityclaude-sonnet-51/5This is a physical laboratory task involving pipetting, fixation, spreading, and staining of cell cultures on slides, requiring fine motor manipulation that current AI systems cannot perform end-to-end.'
Adoption barriersclaude-haiku-4-5-202510014/5Clinical cytogenetics slides often require strict protocol adherence for diagnostic validity and regulatory compliance (CLIA, accreditation); human technologists typically must verify and sign off on slide quality, creating a human-contact requirement and liability barrier to full automation.
Adoption barriersclaude-sonnet-54/5Cytogenetic slide prep for diagnostic purposes typically requires certified/licensed lab personnel under regulatory and accreditation standards (e.g., CLIA), creating strong barriers to full substitution.
Cost vs. human wageclaude-haiku-4-5-202510012/5Robotic slide preparation systems where available are capital-intensive ($50k–$200k+) with moderate throughput gains, making the all-in cost comparable to or higher than trained technologist labor for routine preparation tasks.
Cost vs. human wageclaude-sonnet-51/5Physical automation equipment for slide prep requires expensive specialized robotics and integration, which is not cheaper than a trained technologist performing manual prep.
Technical feasibility todayclaude-haiku-4-5-202510012/5No current deployed AI system performs full slide preparation end-to-end reliably. Some robotic slide stainers and imaging systems exist in specialized labs, but they require significant manual preprocessing and human oversight; production reliability is limited and highly workflow-dependent.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical slide preparation from cell cultures; lab automation robots exist but are not general-purpose AI systems and remain narrow, specialized hardware.

Select appropriate methods of preparation and storage of media to maintain potential of hydrogen (pH), sterility, or ability to support growth.

15

CI 5–25 · exposure 13 · augmentation 38 · importance 4.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical and research laboratories have slow adoption of AI agents for core preparation tasks; most labs use static standard operating procedures and human technologist judgment rather than autonomous recommendation systems.
Sector adoption velocityclaude-sonnet-51/5Clinical cytogenetics labs are a highly specialized, low-digitization physical science sector with minimal AI-driven automation of wet-lab procedures.
Augmentation potentialclaude-haiku-4-5-202510013/5AI could assist by recommending preparation methods based on media type and storage conditions, flagging pH or sterility anomalies from sensor data, or summarizing vendor specifications—useful support but the technologist retains critical validation responsibility.
Augmentation potentialclaude-sonnet-52/5AI could assist with documentation, protocol lookup, or inventory tracking, but offers minimal help with the hands-on judgment needed for media selection and preparation.
Task automatabilityclaude-haiku-4-5-202510012/5While AI could help select preparation methods via lookup or decision trees, the task requires real-time judgment about media pH stability, sterility verification, and growth-supporting conditions that depend on empirical observation and tactile/sensory verification incompatible with full end-to-end automation today.
Task automatabilityclaude-sonnet-51/5This requires hands-on laboratory judgment, physical media preparation, and real-time quality assessment in a wet-lab environment that current AI cannot perform end-to-end.'
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetic work operates under strict regulatory (CLIA, CAP) and quality-control standards requiring documented human accountability; media preparation directly affects diagnostic accuracy and is subject to laboratory accreditation audits that mandate human certification.
Adoption barriersclaude-sonnet-54/5Clinical lab work is governed by CLIA/CAP regulations requiring certified technologists to perform and validate media preparation, creating strong regulatory and liability barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI oversight and integration costs for media selection are comparable to or exceed the marginal cost of a technologist consulting standard protocols and performing spot checks, given the safety-critical nature of the task.
Cost vs. human wageclaude-sonnet-51/5There is no viable AI substitute performing this physical task, so AI cost is effectively infinite relative to human labor for this specific function.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably performs media preparation and storage selection autonomously; laboratory information systems can track protocols, but human technologists must validate pH, sterility, and growth potential through hands-on inspection and measurement.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product autonomously selects and prepares cytogenetic culture media; this remains a manual, technician-performed laboratory task.

Select banding methods to permit identification of chromosome pairs.

15

CI 14–16 · exposure 16 · augmentation 38 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Clinical cytogenetics operates in highly regulated, low-digitization environments with strong quality-control traditions and small, specialized teams. Adoption of autonomous AI decision-making in this field has been minimal; most labs maintain traditional, human-led protocols despite technological advances.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory diagnostics adopt AI cautiously due to regulatory oversight and validation requirements, with automation concentrated in image analysis rather than protocol selection.
Augmentation potentialclaude-haiku-4-5-202510013/5AI tools can assist cytogeneticists by recommending banding methods based on chromosome image quality, reference databases, or clinical indicators, and by automating literature/protocol lookup. Such assistance can raise throughput, but the human expert must remain in the loop to validate selections against lab-specific conditions and diagnostic needs.
Augmentation potentialclaude-sonnet-52/5AI can assist by flagging likely abnormalities or suggesting relevant literature/protocols, but has limited direct impact on the core decision-making of banding method selection today.
Task automatabilityclaude-haiku-4-5-202510012/5Selecting appropriate banding methods requires specialized domain knowledge about cytogenetic protocols, chromosome morphology, and clinical context. While AI could assist in retrieving procedural information or recommending standard protocols, the decision ultimately depends on visual assessment of chromosome quality, lab conditions, and diagnostic goals—factors that demand human expertise and cannot reliably achieve 50% time savings end-to-end today.
Task automatabilityclaude-sonnet-52/5Selecting appropriate banding methods (G-banding, FISH, etc.) requires nuanced case-specific judgment about clinical context, specimen type, and suspected abnormalities that current AI cannot reliably replicate end-to-end.,
Adoption barriersclaude-haiku-4-5-202510014/5Cytogenetic analysis is performed by licensed clinical laboratory professionals working under CLIA and CAP regulations. Chromosome identification methods directly affect diagnostic accuracy in clinical settings, creating liability and quality-assurance requirements that mandate human professional oversight and sign-off on method selection.
Adoption barriersclaude-sonnet-54/5Clinical cytogenetics work is subject to lab accreditation, licensure, and diagnostic liability standards requiring qualified technologists/pathologists to make and validate such protocol decisions.
Cost vs. human wageclaude-haiku-4-5-202510011/5This task requires a trained human cytogeneticist (high-wage specialist labor) to ensure correct method selection. Current AI systems cannot replace this decision-making, so any AI solution would be supplementary, adding cost rather than reducing it compared to human expertise alone.
Cost vs. human wageclaude-sonnet-51/5There is no viable AI substitute performing this specific selection task at scale, so cost comparison favors the human expert who integrates clinical and technical judgment.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed product reliably performs this task autonomously. While AI-assisted chromosome image analysis exists in research settings, selecting banding methods is a specialized decision that requires human cytogeneticist judgment integrated with equipment capabilities and clinical requirements; no production system handles this end-to-end.
Technical feasibility todayclaude-sonnet-51/5No deployed clinical product autonomously selects banding protocols; this remains a technologist/pathologist judgment call embedded in lab workflows, not a productized AI function.

Prepare biological specimens such as amniotic fluids, bone marrow, tumors, chorionic villi, and blood, for chromosome examinations.

13

CI 5–20 · exposure 8 · augmentation 25 · importance 4.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical laboratories are conservative and slow-moving; specimen preparation remains highly manual even in well-resourced centers. Adoption of robotic prep systems is limited to large reference labs and research institutions, not representative of the sector's overall pace.
Sector adoption velocityclaude-sonnet-51/5Clinical laboratory specimen processing is a physical, highly regulated task with minimal AI/robotic adoption to date, unlike digital-first fields.
Augmentation potentialclaude-haiku-4-5-202510012/5AI offers limited in-the-loop assistance for specimen prep itself; image recognition aids downstream slide review, not upstream preparation. The task requires real-time judgment about specimen viability and handling that is not yet meaningfully augmented by AI tools.
Augmentation potentialclaude-sonnet-52/5AI can assist with scheduling, tracking, or documentation around specimen prep, but offers little direct enhancement to the physical preparation steps themselves.
Task automatabilityclaude-haiku-4-5-202510012/5Specimen preparation involves physical manipulation of delicate biological materials, precise centrifugation, fixation, and staining—tasks requiring specialized lab equipment, dexterity, and environmental control that current AI cannot execute end-to-end. While image analysis of prepared slides is automatable, the upstream wet-lab work remains largely manual.
Task automatabilityclaude-sonnet-51/5This is hands-on wet-lab specimen preparation involving physical manipulation of biological material, requiring fine motor skills and sterile technique that current AI cannot perform without robotic embodiment.
Adoption barriersclaude-haiku-4-5-202510014/5Specimen handling is subject to CLIA and CAP regulations requiring documented quality control, chain-of-custody, and human validation of each specimen. Any automation must be validated and approved for clinical use, creating both regulatory and liability barriers to substitution.
Adoption barriersclaude-sonnet-54/5Clinical laboratory work is subject to CLIA regulations, certification requirements, and quality-control standards, and specimen handling errors carry high liability, creating strong regulatory and safety barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5Specialized lab automation equipment is capital-intensive and requires highly trained personnel to supervise. The cost of acquiring, maintaining, and operating robotic specimen-prep systems remains higher than the loaded cost of a cytogenetic technologist performing the task.
Cost vs. human wageclaude-sonnet-51/5There is no AI system substitute for this physical task, so AI cost is effectively infinite relative to human labor for this specific step.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI system performs the full specimen preparation workflow (harvesting, culturing, treating, fixing, and mounting). Robotic liquid handlers exist in some labs but require extensive human setup, calibration, and oversight; this is not a mature, end-to-end automation in production use across the field.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical specimen preparation for cytogenetic analysis; this remains entirely manual laboratory work performed by trained technologists.

Stain slides to make chromosomes visible for microscopy.

7

CI 7–7 · exposure 0 · augmentation 25 · importance 4.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5While some high-volume labs have adopted automated staining instruments, these are specialized laboratory robotics—not AI-driven systems—and adoption remains concentrated in large institutional labs rather than widespread across the sector.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory diagnostics adopt automation slowly due to regulatory certification requirements and reliance on physical lab equipment rather than AI software.
Augmentation potentialclaude-haiku-4-5-202510012/5AI offers minimal assistance for the staining procedure itself; image analysis on already-stained slides is more amenable to AI, but the staining task as stated involves manual wet-lab work where AI provides little productivity enhancement.
Augmentation potentialclaude-sonnet-52/5AI offers minimal direct assistance for the physical staining step itself, though software may help optimize timing/protocols in some advanced lab information systems.
Task automatabilityclaude-haiku-4-5-202510011/5Staining slides is a hands-on laboratory procedure requiring physical manipulation of specimens, reagent application, timing control, and visual inspection for quality—tasks that current AI systems cannot perform end-to-end in real laboratory environments without human supervision and physical automation infrastructure.
Task automatabilityclaude-sonnet-51/5This is a manual, physical wet-lab task involving pipetting reagents, timing chemical reactions, and handling slides—AI cannot manipulate physical lab materials today.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical cytogenetics operates under strict regulatory requirements (CLIA, CAP standards) that mandate qualified personnel oversight; liability for incorrect staining affecting diagnostic accuracy creates high error-cost asymmetry and regulatory barriers to full automation.
Adoption barriersclaude-sonnet-54/5Cytogenetic staining is part of a regulated clinical lab workflow requiring certified technologists and quality control, creating strong regulatory and liability barriers to substitution.
Cost vs. human wageclaude-haiku-4-5-202510011/5The cost of robotic automation hardware, integration, maintenance, and oversight for slide staining would significantly exceed the wage of a skilled technologist performing the task manually, making AI substitution economically unfavorable.
Cost vs. human wageclaude-sonnet-51/5There is no AI-based substitute for physical staining, so AI cost is not comparable; any automation here would require specialized robotic hardware, not general AI, making cost comparison inapplicable/unfavorable.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI product reliably performs the complete staining workflow independently; existing systems lack the embodied capability to handle wet lab protocols, pipetting, timing, and quality verification in production cytogenetics labs.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical slide staining; existing lab automation for staining relies on mechanical/robotic hardware, not AI systems, and is not the same as AI performing the task.

Maintain laboratory equipment such as photomicroscopes, inverted microscopes, and standard darkroom equipment.

5

CI 0–10 · exposure 0 · augmentation 25 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5There is no adoption of AI for equipment maintenance in cytogenetics labs because the physical, hands-on nature of the work is incompatible with current AI capabilities. Labs continue to rely on human technicians and manufacturer service contracts.
Sector adoption velocityclaude-sonnet-51/5Clinical laboratory settings adopt automation slowly for physical maintenance tasks, and this niche task shows no meaningful AI/robotic uptake.
Augmentation potentialclaude-haiku-4-5-202510012/5AI could offer minimal assistance through diagnostic guides or troubleshooting documentation, but the core maintenance work remains manual. An AI-powered troubleshooting chatbot might slightly accelerate problem identification, but the technician must still perform all physical repairs and calibrations.
Augmentation potentialclaude-sonnet-52/5AI could assist with scheduling maintenance, tracking equipment logs, or diagnosing issues via sensor data, but this offers only marginal support to the core physical maintenance work.
Task automatabilityclaude-haiku-4-5-202510011/5Maintaining specialized laboratory equipment requires hands-on physical inspection, calibration, and repair work that cannot be performed remotely or by AI today. The task involves troubleshooting mechanical and optical components, which demands tactile manipulation and real-time human judgment beyond current AI capabilities.
Task automatabilityclaude-sonnet-51/5Equipment maintenance requires physical inspection, cleaning, calibration, and hands-on repair of lab instruments, which current AI cannot perform end-to-end.'
Adoption barriersclaude-haiku-4-5-202510015/5This task has substantial regulatory and safety barriers: manufacturers typically require certified technicians or authorized service providers to maintain laboratory equipment, and improper maintenance could compromise data integrity and safety in a clinical/diagnostic setting. Equipment warranties and laboratory accreditation standards often mandate human oversight.
Adoption barriersclaude-sonnet-53/5No licensing requirement specifically bars automation, but the physical, hands-on nature of equipment maintenance and lab safety protocols create practical friction against any substitution.
Cost vs. human wageclaude-haiku-4-5-202510011/5AI cannot perform this maintenance task at all, making cost comparison moot. Human technicians with specialized training in microscopy and optical equipment remain the only viable option.
Cost vs. human wageclaude-sonnet-51/5There is no viable AI substitute for physical equipment upkeep, so AI cost is effectively infinite relative to human labor for this task.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI system can independently maintain photomicroscopes, inverted microscopes, or darkroom equipment. This task requires physical presence and intervention that falls entirely outside the scope of current AI applications in laboratory settings.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical maintenance of microscopes or darkroom equipment; this remains a manual technician task.

Supervise subordinate laboratory staff.

1

CI 0–3 · exposure 0 · augmentation 38 · importance 3.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Personnel management remains a quintessentially human organizational function with minimal automation adoption even in digitized sectors; no industry data shows meaningful AI displacement of supervisory roles.
Sector adoption velocityclaude-sonnet-52/5Healthcare and clinical lab settings adopt AI slowly for management functions, with most AI use confined to diagnostic assistance rather than personnel supervision.
Augmentation potentialclaude-haiku-4-5-202510012/5AI could assist with scheduling optimization, performance metric dashboards, or flagging compliance issues, but supervisory work—coaching, discipline, accountability—remains fundamentally human and resistant to meaningful augmentation by current tools.
Augmentation potentialclaude-sonnet-53/5AI can help with scheduling, performance tracking, training materials, and administrative reporting, moderately easing supervisory workload without replacing the supervisory role itself.
Task automatabilityclaude-haiku-4-5-202510011/5Supervising subordinate staff requires dynamic interpersonal judgment, conflict resolution, performance evaluation, and adaptive decision-making in response to individual circumstances—capabilities that current AI systems cannot reliably perform end-to-end without constant human oversight.
Task automatabilityclaude-sonnet-51/5Supervising staff involves interpersonal leadership, performance evaluation, scheduling, and conflict resolution requiring human judgment and authority that AI cannot exercise today.
Adoption barriersclaude-haiku-4-5-202510015/5Labor law, HR liability, employment contracts, and organizational governance require a licensed human manager to make binding personnel decisions and hold legal accountability for staff supervision.
Adoption barriersclaude-sonnet-55/5Supervisory roles typically require organizational authority, accountability, and often certification/experience mandated by lab accreditation standards, making legal/organizational substitution essentially impossible.
Cost vs. human wageclaude-haiku-4-5-202510011/5The cost of AI systems that could attempt supervision-adjacent functions (scheduling, monitoring), combined with required human oversight and correction, far exceeds the marginal cost of a human supervisor.
Cost vs. human wageclaude-sonnet-51/5There is no AI system capable of independently performing this task, so cost comparison favors the human by default.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI product reliably manages personnel supervision, performance reviews, or staff discipline independently in production laboratory environments; such tasks require contextual judgment and legal/HR accountability that current systems cannot assume.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs direct supervision of laboratory personnel; management software exists only as a support tool, not a substitute for supervisory authority.

Related occupations — Healthcare Practitioners & Technical

How to read this

A high substitution score does not mean this job disappears — it means a large share of its current tasks face replacement pressure, so the mix of tasks is likely to change. High augmentation alongside substitution typically means the occupation reorganizes around the protected tasks. Wide confidence intervals mean the rater panel disagreed: treat those scores as open questions, not verdicts.

What would change this score

New model capabilities (automatability, feasibility), falling inference costs (cost ratio), regulation and licensing shifts (barriers), and measured sector adoption (velocity) all re-enter at every index release. Each release is recomputed, versioned and kept queryable — scores are claims with a date on them, not permanent labels.